Table 2.
Baseline clinical characteristics of participants in stage CKD 1–5
| CKD 1 | CKD 2 | CKD 3 | CKD 4 | CKD 5 | p | |
|---|---|---|---|---|---|---|
| N = 101 | 23 | 20 | 27 | 13 | 18 | |
| Age (year) | 34.0 ± 9.1 | 40.1 ± 6.1 | 41,7 ± 6,4 | 42.1 ± 5.95 | 38.5 ± 8.32 | n.s. |
| BMI (kg/m2) | 26.1 ± 5.2 | 25.9 ± 5.3 | 25.1 ± 3.6 | 27.3 ± 5.33 | 25.2 ± 2.89 | n.s. |
| Hemoglobin (g/L) | 149.9 ± 7.2 | 146.4 ± 9.1 | 133.8 ± 13.9 | 121.4 ± 12.1 | 111.6 ± 13.3 | <0.001 |
| Creatinine ( μmol/L) | 81.6 ± 11.2 | 110.7 ± 15.2 | 153.1 ± 38.9 | 387 ± 162 | 633.1 ± 203 | <0.001 |
| Cystatin C (mg/L) | 4.26 ± 0.29 | 2.44 ± 0.13 | 1.66 ± 0.12 | 0.98 ± 0.05 | 0.84 ± 0.05 | <0.001 |
| eGFR | 92.6 ± 1.5 | 77.1 ± 9.5 | 47.9 ± 10.0 | 21.1 ± 5.4 | 12.1 ± 2.0 | <0.001 |
CKD staging was tested with one way ANOVA. Data were considered statistically significant at P < 0.05CKD stage was based on Creatinine–Cystatin C Equation) for Estimating GFR (eGFR) [19]